Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 120.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 4, items 1 to 30 of 120.
Investigations in Gestational Origins of Lifetime Development: Understanding health begins before birth. Are you in your first trimester of Pregnancy? 07-0535
To learn more about how your metabolism is connected to your baby's growth and development
  • Healthy Women ages 18-35 who are 10-14 weeks pregnant with single baby.  With a  BMI of 30-38 who are willing to complete 5 visits during pregnancy and agreeable to an infant blood draw at birth and DXA postpartum.  
There is an option to take part in a 1 year follow-up which entails an additional 4 visits and another DXA at 1 year of life.
PI: Barbour, Linda
  • 303-724-3974
  • catherine.chartier-logan@ucdenver.edu
We are Currently Enrolling People with Down syndrome for a study in Dr. Pelak's Brain and Vision Research lab at the University of Colorado Anschutz Medical Campus. 05-1131
To examine visual brain function in people with mild memory impairments to detect early signs of Alzheimer's Disease.​
Persons 19-30 who have Down Syndrome
PI: Pelak, Victoria
  • 303-724-2184
  • Jerri.Lusk@ucdenver.edu
EMERALD STUDY: Effects of MEtformin on CardiovasculaR function in AdoLescents with Type 1 Diabetes 12-1528
​To determine the effects of Metformin on Cardiovascular Function in Adolescents with Type 1 Diabetes.
  • Persons 12-21 who have Type 1 Diabetes
  • Non-smoker, able to ride a stationary bike
  • You must be willing to take metformin or placebo (sugar pill) for 3 months.
  • Other exclusions apply, please contract study for more information
PI: Nadeau, Kristen
  • 720-777-5774 or 720-777-6143
  • susan.gross@childrenscolorado.oramy.baumgartner@childrenscolorado.org
Children's Hospital, department of Pediatric Neurology is conducting a research study 13-0032
Evaluating the effects of a single treatment of injected BOTOX® (Botulinum Toxin Type A) for chronic migraine(s) in adolescents.
  • Adolescents 12-17 who have no serious medical conditions but have at least 15 headaches a month for the last 6 months. 
  • You not have any previous BOTX treatments or are not currently using any prophylactic medicine.
PI: Kedia, Sita
  • 720-777-8588
  • headacheresearch@childrenscolorado.org
Non-Alcoholic Fatty Liver Disease and Obstructive Sleep Apnea: Mechanistic Links between Hypoxemia and Liver Injury 09-0169
To learn if obstructive sleep apnea and low oxygen levels have a role in developing Non-Alcoholic Fatty Liver Disease (NAFLD).​​​
Children 10-17 who have a normal weight and no serious medical problems
PI: Sundaram, Shikha
  • 720-777-3819
  • Kristen.robbins@childrenscolorado.org
Exercise and Cancer Prevention Research Study 13-2314
The goal of this study is to better understand the biological mechanisms associated with exercise and reduced risk for breast cancer.
  • You must be a female between the ages of 30-45 to participate in this study. 
  • You must be planning to live in the Denver metropolitan area for the next 10 consecutive months. 
  • You should not be a regular exerciser because this study is for people who do not exercise right now; however, you should be willing to participate in an exercise program 4 times per week for 16-weeks.
PI: Bryan, Angela
  • 303-492-9549
  • cuchange@colorado.edu
Are you interested in a supervised exercise intervention? 13-3252
Volunteers are needed for a research study to examine the effects of exercise on food intake and appetite regulation.
  • 21-45 years old
  • Non- smoker
  • Non- Diabetic
  • Exercise no more than 1 time a week
  • Maintained your current weight for last 6 months
  • Have a body mass index (BMI) of 27-35 (check it out at http://nhlbisupport.com/bmi/)
PI: Cornier, Marc
  • 303-724-9024
  • allison.hild@ucdenver.edu
Study of Mood Disorder in Preschool Children 07-0932
We are doing a research study to better understand what mood disorders look like in preschool children.
We are looking for volunteers who:  
  • Are parents of children between the ages of 4 and 6 years 0 months.
  • Are in one of three groups:
    1. Their child has no major mental health problems, and there is no family history of major mood or psychotic disorders.
    2. Their child has been diagnosed with a mood disorder, bipolar disorder, or mood dysregulation disorder. 
    3. Their child has been diagnosed with attention deficit hyperactivity  disorder (ADHD).  
  • Parents or guardians will be asked to:
    • Read and sign a consent form
    • Participate in interviews about their children
  • The  children will be asked to:
    • Participate in a story game
    • Take tests of verbal and nonverbal abilities
How much time will this take?
The visit for the child will last from 1 to 2 hours.  The visit for the parents will last 3 to 5 hours.
PI: Ross, Randy
  • 303-724-6200
  • Kate.Noonan@ucdenver.edu
Understanding how Tysabri and Gilenya Influence the Quality of your Daily Life with Multiple Sclerosis 13-2767
The purpose of this research study is to compare two medications, Tysabri and Gilenya, used in the treatment of multiple sclerosis (MS), through a few self reported patient surveys. We will ask you to complete online surveys about overall health-related quality of life, disability, fatigue, cognition and productivity. We will also want to review your medical records to understand your MS history with your permission. This study will help us understand how these drugs are impacting each aspect of your daily lives.
  • Between ages 16 and 65
  • Scheduled to start natalizumab or fingolimod for the first time to treat your MS
PI: Nair, Kavita
  • 303-724-8388
  • Eric.Engebretson@ucdenver.edu
Living with MS? 12-1522
To evaluate the safety of a new investigational drug that may help reduce relapses.
  • Between the ages of 18 to 65
  • Participants must have relapsing-remitting multiple sclerosis (RRMS)
PI: Corboy, John
  • 303-724-7421
  • Kristina.Bliss@ucdenver.edu
High Altitude Research Study 14-1514
Subjects needed for a study on how high altitude affects cognitive performance
Male and Female subjects needed that are:
  • Between the ages of 18-45 years old and exercise regularly
  • Healthy: non smokers and not on medications
  • Willing to stay below 7,000 ft for 3 weeks prior to altitude chamber day
PI: Roach, Robert
  • 303-724-1674
  • altituderesearch@ucdenver.edu
Are you Pregnant or a Nursing Mother? Consider being a part f a Breast Cancer Research. 12-0769
This study will examine changes that occur in the breast tissue, blood and urine of a woman after she has given birth to a child. The study will examine how a woman’s breast and her cells change after pregnancy and breast feeding and how her immune system interacts with these changes. The immune system is a complex network of cells that identify our tissues as “self” or “foreign” as well as normal cells or cancer cells. We hope to discover how a woman’s breast changes after pregnancy or breast feeding to see if this time point in a woman’s life could be targeted to prevent breast cancer.
You are being asked to be in this research study because you are pregnant or were recently pregnant and have not had breast cancer or another autoimmune disease.
PI: Borges, Virginia
  • 303-724-6077
  • emily.rozzo@ucdenver.edu
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls 13-2927
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
You may qualify for this research study of you are: A Relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years OR A healthy individuals 18-55 years old without MS or other neurological conditions
PI: Miravalle, Augusto
  • 303-724-8388
  • Eric.engebretson@ucdenver.edu
Do You have type 1 diabetes? 14-2423
To learn more about an investigation study drug
    • Persons 18 to 30 years who have had Type 1 Diabetes for 12 months
    • Have a stable insulin treatment (MDI or pump) 3 months and an A1C 9.0
    • Not using an antidiabetic agent other than insulin or insulin analogue
    • Willing to take study drug or placebo pills daily for 3 months
    • Not pregnant, breast-feeding or intending to become pregnant
    • Other inclusion/exclusions apply, please contact study coordinator for more information
 
PI: Paul R, Wadwa
  • 303-724-9267
  • cierra.sullivan@ucdenver.edu
Will You Be a Caregiver For Your Loved One During Transplant? 13-2639
We are conducting a research study to assess treatments to reduce the effects of stress on caregivers of patients experiencing an allogeneic transplant.
Patient inclusion criteria include: 1) receiving an allogeneic HSCT, 2) able to read and speak English, 3) telephone access. Caregiver inclusion criteria include: 1) the person in the patient's life who is primarily responsible for care decisions, emotionally invested in the patient's care, provides instrumental care such as transportation, and available if randomized to the fPER group to participate in the majority of intervention sessions, 2) able to read and speak English, 3) willingness to use a Smartphone, 4) absence of a serious medical condition likely to influence hair cortisol, 5) no steroid medications, and 6) over the age of 18 years.
PI: Laudenslager, Mark
  • 303-724-9279
  • Carewell@ucdenver.edu
DO YOU HAVE GESTATIONAL DIABETES? Would you like help with your GDM Diet? 14-1358
Research Subjects Needed to Participate in a Diet Research Study in Women with Gestational Diabetes
Who can qualify? * Highly motivated pregnant women with Gestational Diabetes not taking medicine for blood sugar control * Women willing to follow 1 of 2 healthy diets for blood sugar control * Women willing to complete 6 visits during pregnancy with infant follow up * Gestational age: <31 weeks; singleton pregnancy * Healthy  women, age : 20-36 years * No high blood pressure * Overweight or Obese
PI: Hernandez, Teri
  • 303-724-3974
  • catherine.chartier-logan@ucdenver.edu
Volunteers needed for a NASH therapeutic trial 14-2108
Clinical research study of an investigational product for the treatment of non-alcoholic steatohepatitis (NASH)
*≥18 years old *Confirmed diagnosis of NASH *No other liver disease *No excessive alcohol use (no more than 2 drinks/day for women and 3 drinks/day for men)
PI: Bambha, Kiran
  • 303-724-1871
  • colin.jenks@ucdenver.edu
Brown Adipose Tissue and Estrogen (BATE Study) 13-0149
To investigate whether estrogen influences the activity of brown adipose tissue.
Healthy non-smoking women 20-40 who have regular menstrual cycles and are not on hormonal contraceptives and exercise more than once per week
PI: Melanson, Edward
  • 720-848-6399
  • Kimberly.Harner@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 11-0909
Perceived exertion during exercise
Person 50-70 with or without Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure.  You should have a BMI between 25-35 and have not smoked for a least one year.
PI: Huebschmann, Amy
  • 303-724-2255
  • Ian.Leavitt@ucdenver.edu
Is your child 6-18 years old and interested in participating in a research study? 13-2073
To study the effects of polycystic kidney disease (PKD) on blood vessel function
Children 6-22 free from kidney disease and other chronic diseases
PI: Jablonski, Kristin
  • 303-724-7791
  • Heather.Farmer@ucdenver.edu
Participants Ages 12-15 years old Needed for Research Study 04-0311
To learn about how children with absence epilepsy compare to healthy children in areas such as behavior, neuropsychological skills and quality of life.
Healthy hispanic individuals who are 12-15 years; No history of seizures, seizure like episodes, neurological diseases or a loss of consciousness greater than 5 minutes in their immediate family
PI: Levisohn, Paul
  • 720-777-8608
  • Nanastasia.Welnick@childrenscolorado.org
MRI and Questionnaire Research Study for Patients with MS Taking Tysabri and Healthy Controls 13-2927
This research study plans to learn more about the differences in brain scans and self-reported quality of life between MS patients taking natalizumab (Tysabri) and individuals without MS.
A relapsing Multiple Sclerosis patient 18-55 years old who has been taking Tysabri (natalizumab) for at least 2 years

OR

A healthy individual 18-55 years old without Multiple Sclerosis or other neurological conditions
PI: Miravalle, Augusto
  • 303-724-8388
  • Eric.Engebretson@ucdenver.edu
Healthy Hispanic Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity.
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions or permanent metal implants or braces/retainers and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Participants Needed for an Exercise Study for People with Multiple Sclerosis 14-0295
Researchers from the Neurophysiology of Movement Laboratory on the University of Colorado Boulder campus and the Multiple Sclerosis Center on the University of Colorado Anschutz Medical Campus are conducting a study to investigate the capacity of neuromuscular electrical stimulation to improve walking in persons with multiple sclerosis.
-Between 18 to 55 years of age -Have clinically confirmed diagnosis of MS -Are able to talk but have some difficulty walking
PI: Enoka, Roger
  • 303-724-4644
  • Roger.Enoka@colorado.edu
HIV-V-A004 - Learn More About A Clinical Research Study For Investigational HIV Vaccines. 14-2056
The purpose of this study is to assess the safety and immune system response to investigational HIV vaccines in healthy, HIV-uninfected adult volunteers. These assessments will help researchers plan future vaccine studies.
- Willing to participate and who understand the purpose and procedures of the study „- 18 – 50 years of age „- HIV-uninfected „- In good health „- Willing to maintain behavior consistent with low risk HIV exposure
PI: Campbell, MD, Thomas
  • 303-724-0801
  • dana.momeyer@ucdenver.edu
Healthy Adolescents Needed 07-0709
Psychological study on how flexible your brain can shift from one task to another.
-Female -age 12-17 years old -in good health -on no medication
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Help test a mobile app for postpartum moms 14-1173
This research study will test a mobile application to learn more about how to best deliver information about diet and physical activity for postpartum women at elevated risk for diabetes and heart disease.
You may qualify for this study if you:  Are between 18-45 years old  Are in your third trimester of pregnancy or have given birth in the last 24 weeks  Have a postpartum BMI: 25-45 kg/m2  Have access to and be willing to use a wi-fi enabled iPhone or an iPod  Have a history of one or more of the following complications in your most recent pregnancy: o Gestational diabetes mellitus o Preeclampsia o Gestational hypertension o Pre-term delivery (32-37) weeks o Small for gestational age (
PI: Nicklas , Jacinda
  • 303-724-8898
  • jessica.jaramillo@ucdenver.edu
Type 1 Diabetes Research Study 11-0649
To study the effects of a medication on metabolism and blood vessel function.
Persons 25-50 years old with or without type 1 diabetes with normal blood pressure and exercise vigorously no greater than 3 times per week.
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
  • Brittany.Kling@ucdenver.edu
JUST DIAGNOSED WITH SHINGLES? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of shingles. 1-2 study visits for blood draws, over the course of 3 months.
18+ years of age; NO PRIOR HISTORY of shingles; have NEVER received the shingles vaccine; have DEVELOPED SHINGLES within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 24, items 1 to 30 of 706.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 24, items 1 to 30 of 706.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS. Sponsor Protocol No. RPC02-201. WIRB Protocol No. 20140555
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo. Sponsor Protocol No. PM1116197. WIRB Protocol No. 20141040
Krantz, Mori14-1331
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy Sponsor Protocol No. 13-005 WIRB Protocol No. 20141141
Halbower, Ann14-1333
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects with Chronic Rhinosinusitis with Nasal Polyps. Sponsor Protocol No. 20110236. WIRB Protocol No. 20150667
Kingdom, Todd14-1371
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Sponsor Protocol No. D5160C00008 WIRB Protocol No. 20142209
O'Bryant, Cindy14-1390
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFET Sponsor Protocol No. RPC02-201 WIRB Protocol No. 20140555
Fleischer, David14-1399
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study Sponsor Protocol No. 191622-111 WIRB Protocol No. 20132162
Biffl, Susan14-1404
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study Protocol No. 191622-112 WIRB Protocol No. 20132135
Biffl, Susan14-1405
An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor Protocol No. M14-224. WIRB Protocol No. 20142269
Everson, Greg14-1435
A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma. Sponsor Protocol No. SAS115358. WIRB Protocol No. 20111924
Anderson, William14-1445
A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA Sponsor Protocol No. GO29365 WIRB Protocol No. 20141475
Gutman, Jonathan14-1455
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases Treated with Hormonal Treatment Background Therapy Sponsor Protocol No. BAY 88-8223 / 16298 WIRB Protocol No. 20150791
Fisher, Christine14-1465
Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors. Sponsor Protocol No. GO29313. WIRB Protocol No. 20141118
Camidge, David14-1476
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer. Sponsor Protocol No. M14-361. WIRB Protocol No. 20142537
Camidge, David14-1489
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). Sponsor Protocol No. M14-868. WIRB Protocol No. 20141974
Everson, Greg14-1494
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection. Sponsor Protocol No. 2014-01. WIRB Protocol No. 20141261
Freeman, Stephen14-1538
A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS Sponsor Protocol No. GO29146 WIRB Protocol No. 20140268
Weekes, Colin14-1551
TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Sponsor Protocol No. CO-1686-022 WIRB Protocol No. 20142085
Camidge, David14-1569
An Open-Label, Multi-Center, 48-Week Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy. Sponsor Protocol No. 4658-301-a1. WIRB Protocol No. 20141230
Parsons, Julie14-1629
Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma Sponsor Protocol No. PIN-PHO1201 WIRB Protocol No. 20140456
Shah, Raj14-1650
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease. Sponsor Protocol No. RECD3125. WIRB Protocol No. 20141667
Gerich, Mark14-1659
A Comparison of Soy Protein versus Soy-Dairy Protein-blend Containing Foods in the Colorado Diet for Weight loss and Maintenance. WIRB Protocol No. 20150081
Hill, James14-1666
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy Sponsor Protocol No. ALDOXORUBICIN-P2-SCLC-01 WIRB Protocol No. 20141373
Doebele, Robert14-1673


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more